ARO-C3

DRUG2 trials

Sponsors

Arrowhead Pharmaceuticals Inc., Arrowhead Pharmaceuticals

Conditions

C3 GlomerulopathyIgA Nephropathycomplement-mediated renal disease

Phase 1

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

CompletedNCT05083364

Arrowhead PharmaceuticalsC3 Glomerulopathy, IgA Nephropathy

Start: 2022-02-01End: 2025-09-10Updated: 2026-05-22

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease

Active, not recruitingCTIS2023-506690-36-00

Arrowhead Pharmaceuticals Inc.complement-mediated renal disease

Start: 2024-05-06Target: 5Updated: 2025-08-15